Cancer Patients Can Benefit from Medicare Drug Payment Plan: Study

A new study suggests that older adults with cancer may be especially good candidates for a little-known Medicare benefit that can make expensive prescription drugs easier to manage financially.

Researchers found that the Medicare Prescription Payment Plan, sometimes called M3P, can significantly reduce the financial strain that often hits Medicare beneficiaries early in the year, when high-cost medications sometimes must be paid upfront. That's because it allows Part D enrollees to finance, with no interest, the cost of high-priced medications over 12 payments instead of a lump sum.

The study, published Jan. 15 in the Journal of Clinical Oncology, focused on seniors with cancer because they are more likely to take costly specialty drugs and reach Medicare Part D's out-of-pocket limits quickly.

But the researchers stressed that the payment plan is not limited to cancer patients. Any Medicare beneficiary enrolled in a Part D prescription drug plan can use it.

How M3P works

Under traditional Medicare Part D coverage, beneficiaries may face large out-of-pocket costs at the beginning of the year, especially if they take brand-name or specialty medications. In some cases, a single prescription filled in January can cost hundreds or even thousands of dollars.

Here's how M3P works:

• The Part D plan pays the full cost of the prescription at the pharmacy.

• The beneficiary repays the plan through interest-free monthly installments.

• Payments are adjusted based on the number of months left in the year and any new prescriptions.

• Once a beneficiary reaches Medicare's catastrophic coverage phase ($2,100 in 2026), they owe no additional cost-sharing for covered drugs but continue paying down any remaining balance through the monthly payments.

For seniors living on fixed incomes, this can turn a large, one-time bill into predictable monthly payments.

Why the study focused on cancer patients

The research team analyzed prescription claims from a national sample of Medicare beneficiaries with cancer and projected how their costs would look in 2025.

Nearly half of those beneficiaries were expected to hit Medicare's out-of-pocket cap during the year, and about one-third were projected to reach it as early as January. Without the payment plan, that meant extremely front-loaded expenses.

When researchers simulated enrollment in M3P, monthly payment swings dropped sharply, especially for people who would otherwise face large January bills. The effect was strongest among patients who had struggled to afford medications in the past — a sign that the program could help reduce cost-related medication nonadherence.

The takeaway

Medicare Part D plans are required to send beneficiaries a letter each year explaining the program, but there is no requirement that doctors or pharmacists discuss it.

If you are enrolled in a Medicare Part D plan and expect high prescription costs, you can contact your plan directly to ask about enrolling. Participation is voluntary, and it is generally most helpful if you sign up before the start of the year, especially if you know you will need expensive medications early on.

Also, M3P is not just for cancer patients. Any Medicare beneficiary with a Part D plan who faces high prescription costs — whether for cancer, autoimmune diseases, heart conditions or other illnesses — can use it. If you have questions, please give us a call.